新型阴茎牵引装置改善前列腺切除术后阴茎长度与勃起功能:单中心随机对照试验
该单中心随机对照试验纳入82例前列腺切除术后男性,比较阴茎牵引治疗与对照在6个月时的效果。结果显示牵引组在牵伸阴茎长度、勃起功能、性交满意度及总体性满意度方面均优于对照组,且勃起辅助治疗使用更少,不良事件轻微短暂。
要点
- 前列腺切除术后每日使用阴茎牵引装置6个月可改善或保留阴茎长度。
- 牵引组勃起功能与性满意度优于对照组,且阴茎海绵体注射使用率更低。
- 不良事件轻微短暂,多数患者愿意重复并推荐该治疗。
核心结论
- 新型阴茎牵引装置在前列腺切除术后可显著改善客观与主观阴茎长度及勃起功能相关指标。
研究设计与样本
- 单中心随机对照试验,82例前列腺切除术后男性随机分入对照组或两种阴茎牵引方案之一,治疗6个月。
主要发现
- 6个月时牵引组阴茎长度变化+1.6 cm,对照组+0.3 cm,p<0.01。
- 牵引组IIEF勃起功能评分变化+0,对照组-6.5,p=0.03。
- 牵引组IIEF性交满意度变化+1,对照组-3.5,p<0.01。
- 牵引组IIEF总体性满意度变化0,对照组-3,p<0.01。
- 阴茎海绵体注射使用率牵引组19%,对照组50%,p<0.05;磷酸二酯酶5抑制剂使用率86% vs 94%,p=0.44。
临床怎么用
- 对于前列腺切除术后希望改善阴茎长度和勃起功能的患者,可考虑使用该阴茎牵引装置。
- 治疗期间不良事件轻微短暂,患者满意度较高,可作为非药物治疗选择之一。
局限性
- 单中心研究,需外部验证。
- 随机阶段6个月数据仅纳入25例对照和30例牵引病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: RestoreX is a novel penile traction therapy device, with randomized, controlled data demonstrating improvements in penile length and erectile function after 30 to 90 minutes of daily use in men with Peyronie's disease. We sought to determine if similar improvements could be achieved post prostatectomy. MATERIALS AND METHODS: Men post prostatectomy were randomly assigned to control or one of 2 penile traction therapy protocols for 6 months, followed by a 3-month open-label phase. The current study presents data from the randomized phase. The primary outcome was changes in stretched penile length; secondary outcomes were changes in International Index of Erectile Function (IIEF) scores, adverse events, satisfaction and subjective measures. RESULTS: In all, 82 men (mean age 58.6 years) were randomized, with 6-month data available in 25 controls and 30 penile traction therapy cases. At 6 months, penile traction therapy achieved greater improvements/preservation of penile length (+1.6 vs +0.3 cm, p <0.01), erectile function (IIEF-Erectile Function +0 vs -6.5, p=0.03), intercourse satisfaction (IIEF-Intercourse Satisfaction +1 vs -3.5, p <0.01) and overall sexual satisfaction (IIEF-Overall Sexual Satisfaction 0 vs -3, p <0.01). Erectogenic therapy use was lower in penile traction therapy men (phosphodiesterase-5 inhibitors 86% vs 94%, p=0.44; intracavernosal injections 19% vs 50%, p <0.05). More penile traction therapy men reported satisfaction or improvement in penile length than controls. Adverse events were transient and mild; 87% would choose to repeat therapy, and 93% would recommend it to others. CONCLUSIONS: The use of a novel penile traction therapy device results in significant improvements in objective and subjective penile length post prostatectomy and measures of erectile function, intercourse satisfaction and overall sexual satisfaction. External validation is warranted.
引用
- Toussi A, Ziegelmann M, Yang D, et al. Efficacy of a Novel Penile Traction Device in Improving Penile Length and Erectile Function Post Prostatectomy: Results from a Single-Center Randomized, Controlled Trial. J Urol. 2021. PMID: 34060339. doi:10.1097/JU.0000000000001792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。